AIM Immunotech is a biopharmaceutical company based in Ocala, Florida, focused on developing innovative solutions for a range of debilitating and life-threatening conditions. Their lead program, Ampligen, is an immuno-modulator that has shown broad-spectrum activity in in vitro and animal testing, with ongoing clinical studies for oncology, immune disorders, and viral diseases.
The company aims to improve patient outcomes by advancing therapeutic solutions that have the potential to address unmet medical needs across various disease areas. AIM Immunotech's commitment to research and development is evident through their scientific publications, clinical trials, and partnerships in the fields of immuno-oncology, immune disorders, and viral diseases.
Generated from the website